- POAI subsidiary inks contract with significant pharmaceutical company
- TumorGenesis announces sale of media to research medical centers in New York City, Boston
- Potential market for 3D cancer cell culture media expected to reach $3.2 billion sales worldwide by 2027
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that one of its wholly owned subsidiaries, Soluble Biotech, recently inked another contract with a large pharmaceutical company (https://ibn.fm/OpaJb). POAI also announced that TumorGenesis, one of its wholly owned subsidiaries, has sold media to two top research medical centers (https://ibn.fm/uXorQ).
Soluble Biotech’s contract will involve using the company’s proprietary protein formulation technology to improve the solubility and stability of a protein therapeutic destined for future clinical use.
“This opportunity may also lead to a long-term relationship whereby Soluble Biotech develops a strategic partnership to support several other therapeutics currently under development within the pharmaceutical company,” said Soluble Biotech Founder and President Dr. Larry DeLucas.
In additional company news, Predictive Oncology shared details about the sale of media to two top research medical centers. The sales by TumorGenesis, POAI’s wholly owned subsidiary, were repeat orders from hospitals in New York City and Boston, and included culturing ovarian cancer cells with specific research goals.
“We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease,” said Predictive Oncology President and CEO Dr. Carl Schwartz. “In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step.” POAI is committed to this first step and is the process of building the largest existing database of drug response data in the world.
The announcement noted that TumorGenesis can replicate ovarian cancer cells in a laboratory—outside of the patient’s body. The company has 15 ovarian cancer cell lines along with the media to grow those cells.
“These tissues, in the right TumorGenesis media, replicate not only the DNA/RNA and proteomic signatures but also replicate the histological structures that can be seen in staining, outside the patient’s body,” said TumorGenesis President and board member Richard Gabriel. The process produces invaluable information that can be used by oncologists and other cancer treatment experts to potentially identify and prescribe treatments and care for cancer patients, resulting in more positive outcomes.
The potential market for what POAI does — 3D cancer cell culture media — is expected to reach $3.2 billion sales worldwide by 2027. The space is so explosive because it currently offers the best available models for cancer drug discovery and development.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of more than 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.